Innate Pharma Beats Estimates and Secures Cash Runway to 2028 via Sobi Deal

Key Facts

1Innate Pharma reported an EPS of -$0.24, beating the analyst consensus estimate of -$0.29.

2The company finalized a strategic partnership with Sobi including a $75 million upfront payment, extending its cash runway through Q1 2028.

3The company posted revenue of $6.5 million, exceeding the estimated $6.35 million.

In a move reflecting the resilience of biotech firms navigating funding challenges, Innate Pharma reported financial results that surpassed market expectations. The company posted an EPS of -$0.24, beating the analyst consensus estimate of -$0.29. Additionally, revenue reached $6.5 million, exceeding the projected $6.35 million, strengthening confidence in the company's financial trajectory during this phase.

This financial performance coincided with the finalization of a strategic partnership with Sobi for lacutamab, which included a $75 million upfront payment for Innate Pharma. According to reports, this new funding extends the company's cash runway through the first quarter of 2028, a critical development given the company's current ratio of 0.60, highlighting the necessity of this cash injection to cover short-term obligations and sustain R&D activities.

Regarding price levels, IPHA stood at $1.91 (close September 17, 2026), with a session high of $1.99. With no major upcoming economic catalysts specifically targeting the biotech sector in the immediate calendar, investors will focus on how the company utilizes its new liquidity to advance its clinical pipeline, particularly as current market valuation reflects high expectations for future growth.